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Abstract
Despite the successes achieved with molecular targeted inhibition of the oncogenic driver Bcr-Abl in chronic myeloid
leukemia (CML), the majority of patients still require lifelong tyrosine kinase inhibitor (TKI) therapy. This is primarily
caused by resisting leukemic stem cells (LSCs), which prevent achievement of treatment-free remission in all patients. Here
we describe the ITIM (immunoreceptor tyrosine-based inhibition motif)-containing Fc gamma receptor IIb (FcγRIIb,
CD32b) for being critical in LSC resistance and show that targeting FcγRIIb downstream signaling, by using a Food and
Drug Administration-approved BTK inhibitor, provides a successful therapeutic approach. First, we identified FcγRIIb
upregulation in primary CML stem cells. FcγRIIb depletion caused reduced serial re-plaiting efficiency and cell proliferation
in malignant cells. FcγRIIb targeting in both a transgenic and retroviral CML mouse model provided in vivo evidence for
successful LSC reduction. Subsequently, we identified BTK as a main downstream mediator and targeting the Bcr-Abl-
FcγRIIb-BTK axis in primary CML CD34+ cells using ibrutinib, in combination with standard TKI therapy, significantly
increased apoptosis in quiescent CML stem cells thereby contributing to the eradication of LSCs.. As a potential curative
therapeutic approach, we therefore suggest combining Bcr-Abl TKI therapy along with BTK inhibition.
Introduction
Chronic myeloid leukemia (CML) is caused by the Bcr-Abl
translocation arising in the hematopoietic stem cell (HSC)
compartment. The oncogenic Bcr-Abl tyrosine kinase induces
a variety of signaling pathways that result in increased pro-
liferation, differentiation, cytokine independence, and pro-
tection from apoptosis in the malignant cell clones [1–3].
Implementation of Bcr-Abl tyrosine kinase inhibitors (TKIs)
showed remarkable clinical success with high response rates
[4]. However, current therapies are often not curative, and
even in patients responding optimally to Bcr-Abl inhibition,
TKI discontinuation induces molecular relapse in about half
of this patient cohort [5–7]. Bcr-Abl-positive HSCs are
termed leukemic stem cells (LSCs) and this cell compartment
contains quiescent cells that at least partially resist Bcr-Abl
inhibition [8, 9]. Quiescent LSCs therefore differ from cycling
CML cells that usually undergo apoptosis upon Bcr-Abl tar-
geting [10, 11]. These resistant LSCs persist despite long-term
TKI therapy in CML patients and are most likely the cause of
disease recurrence upon TKI discontinuation. To increase the
amount of patients achieving and remaining in treatment-free
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remission (TFR) therefore requires successful targeting of
these LSCs.
Among many others, targeting JAK/STAT, IL-1, p53/
MYC signaling, or metabolic activity has recently been
shown to impair LSC survival [12–16]. Eventually, these
observations have given rise to clinical trials, but successful
implementation into routine clinical application could not
be achieved so far.
ITIM (immunoreceptor tyrosine-based inhibition motif)
receptors are classified as negative regulators, as they can
recruit phosphatases and in this way inhibit signal transduc-
tion. The ITIM-receptor Fc gamma receptor IIb (FcγRIIb,
CD32b) is a member of the Fc receptor family, which is
known for their function to equalize signaling pathways and
cell activation, leading to a well-balanced immune response
[17]. FcγRIIb is most broadly expressed on all leukocytes
except natural killer and T cells, is the only member trans-
mitting inhibitory signals, and is predominantly phosphory-
lated by the SRC family kinase LYN [18]. FcγRIIb was
previously identified as a cooperative oncogene upon disease
progression in a preleukemic NUP98-HOXA9 mouse model
[19]. Recently, ITIM motif containing receptors LAIR1 and
PirB were identified to support acute myeloid leukemia
(AML) stem cell survival [20, 21], highlighting the impor-
tance of those receptor types for LSC biology.
In this study, we identified TKI-independent upregula-
tion of the ITIM-containing receptor FcγRIIb in primary
murine leukemic stem and progenitor cells, as well as in
primitive CML patient-derived CD34+ cells. Genetic
depletion as well as short hairpin RNA (shRNA)-mediated
knockdown impaired disease phenotype and LSC burden
in vivo in a transgenic and retroviral CML mouse model.
Subsequently, we identified the tyrosine kinase BTK as a
main target of altered FcγRIIb downstream signaling, with
BTK being activated only in FcγRIIb-expressing malignant
cells. Implementation of ibrutinib (Ibr) to target BTK in
combination with standard TKI therapy increased apoptosis
in quiescent CML CD34+ cells providing a novel curative
approach using a Food and Drug Administration (FDA)-
approved drug, aiming to eradicate persisting LSCs.
Materials and methods
Isolation and cell culture of primary cells
Murine lin− bone marrow (BM) cells were isolated and
applied with or without HoxB8-driven immortalization that
was performed as described [22, 23]. Mononucleated cells
(MNCs) were purified by density gradient centrifugation
from peripheral blood (PB), leukapheresis, or BM biopsy
(Ficoll, GE Healthcare, Solingen, Germany), and then cul-
tured in Iscove’s modified Dulbecco’s medium and 20%
BIT9500 (Stem Cell Technologies). Isolation of CD34+
cells was performed from leukapheresis or BM biopsies
using CliniMACS-CD34 or CD34-MicroBead Kit (human,
Milteny Biotech, Bergisch Gladbach, Germany). For
experimental procedures, cells were kept in low growth
factor cocktail [9]. All cytokines were purchased from
ImmunoTools (Friesoythe, Germany) or Milteny Biotech.
Retroviral transduction
Retroviral transduction was performed as described pre-
viously [24] using CaCl2 for transfection and retronectin
(Takara Bio Inc., France) for transduction. Transduction
was repeated two to three times on consecutive days.
RNA expression analysis
Differential expression analysis shown in Supplementary
Fig. S17 was performed on the Gene Expression Omnibus
dataset GSE2535. Data were acquired and analyzed using
the GEOquery and limma R packages. Limma’s voom
normalization and linear model fitting procedure were
applied to the data in order to obtain the differentially
expressed genes. We considered the origin of the samples
(Leipzig vs. Mannheim) as a batch-effect covariate and
corrected for such when fitting the model. As in
GSE2535_REF, non-adjusted p values were used to identify
the most differentially expressed genes. RNA extraction
was performed using Trizol reagent (Thermo Fisher Sci-
entific, Waltham, MA, USA). One microgram of total RNA
was subjected to complementary DNA (cDNA) synthesis
using the Moloney murine leukemia virus reverse tran-
scriptase (Thermo Fisher). Gene expression was analyzed
using TaqMan assays or SYBR Green method as described
previously [25]. TaqMan Assays were purchased from
Applied Biosystems (human FcγRIIb: Hs01634996_s1;
murine FcγRIIb: Mm00438875_m1). Sequences for primer
and probes are available in Supplementary Table S1.
DNA constructs
FcγRIIb cDNA was amplified from cDNA of C57BL/6
wild-type BM using the following primer pairs:
FcγRIIb_XhoI_F: GAACTCGAGATGGGAATCCTGCCG
TTCCT and FcγRIIb_EcoRI_R: GAAGAATTCCTAAA
TGTGGTTCTGGTAAT. PCR product and MSCV-IRES-
GFP vector were digested using XhoI and EcoRI. Positive
clones were fully sequenced.
FcγRIIb shRNA constructs
FcγRIIb targeting shRNA and scrambled (scr) control
shRNA retroviral constructs were generated using pMSCV-
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LTR-miR30-SV40-GFP vectors. shRNA oligonucleotide
sequences are available in Supplementary Table S2.
Cell culture
32Dcl3 (named as 32D), K562, and KCL-22 (DSMZ, ACC
411, ACC 10, ACC 519) cells were cultured in RPMI media
supplemented with 10–20% fetal bovine serum and 1%
penicillin/streptomycin. Ten percent WEHI supernatant was
used as IL-3 source.
Colony formation assay
Indicated cell numbers were resuspended in methylcellulose
(MethoCult M3231, M3534, H4230 and H4434, Stem Cell
Technologies) and colony-forming units were counted after
7–9 days.
Immunoblotting
Immunoblotting was performed as described previously
[23]. The following antibodies were used for immunoblot-
ting p27, pSTAT5Y694, STAT5, pCRKLY207; CRKL,
pBTKY223, BTK, pERKY202/204; ERK, pp38Y180/182,
p38, pcAbl, cAbl (Cell Signaling/New England Biolabs,
Frankfurt, Germany), SHIP1 (N1), FcγRIIb (N16), GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), GFP
(Rockland, Limerick, PA, USA), pFcγRIIb (LifeSpan
BioScience, Seattle, WA, USA), and Tubulin (Sigma-
Aldrich, St. Louis, MO, USA). Protein detection was per-
formed using Fusion SL chemoluminescence detector
(PeqLab, Erlangen, Germany).
Mice and genotyping
C567BL/6 FcγRIIb−/− mice were purchased from Taconic
(Cologne, Germany). Genotyping was performed using
FcγRIIb_Neo_F:ATCGCCTTCTATCGCCTTCT; FcγRIIb_
WT_F: TGCTTTACCCTGCTGAGGAT; FcγRIIb_WT_R:
GGTCTGCTCCATTTGACACC enabling the identifica-
tion of mutant FcγRIIb knockout (253 bp), wild-type (439
bp), or heterozygous (253 and 439 bp) mice. C567BL/6
wild-types were purchased from Janvier Labs (Genest-
Saint-Isle, France). Genotyping of SCLtTA/Bcr-Abl mice
was described previously [26]. FVB/N CD45.2 recipients
were bred in-house.
BM transplantation
BM cells from C567BL/6 FcγRIIb−/−, C567BL/6 FcγRIIb+/+
wild-type, and SCLtTA/Bcr-Abl mice were isolated
4 days after 5-FU injection. BM cells were retrovirally
infected using MSCV-IRES-ev (empty vector)-GFP,
MSCV-IRES-Bcr-Abl-GFP, MSCV-LTR-miR30-SV40-
GFP-shRNA:scr, or MSCV-LTR-miR30-SV40-GFP-
shRNA:FcγRIIb. Briefly, 1200 GFP+ Bcr-Abl-infected cells
were transplanted together with 1 × 105 wild-type rescue
BM cells into 11 Gy irritated C567BL/6 wild-type reci-
pients. Recipients were sacrificed for analyses 15 days after
transplantation. A total of 2.5 × 106 cells from LTR-miR30-
SV40-GFP-shRNA:scr (shRNA:scr) and MSCV-LTR-
miR30-SV40-GFP-shRNA:FcγRIIb (shRNA:FcγRIIb)
non-fluorescence-activated cell sorting (FACS) sorted
SCLtTA/Bcr-Abl BM cells were transplanted via tail vein
injection into 10 Gy irradiated FVB/N CD45.2 mice. Mice
were kept on cotrimoxazole (Ratiopharm, Ulm, Germany)
for 1 week after transplantation.
Ethics approval and consent to participate
Application of human samples was approved by the local
ethics board of the medical faculty RWTH Aachen (EK127/
12, EK206/09). Informed consent was obtained from
all patients. All animal experiments were approved
by the local authorities (Landesamt für Natur, Umwelt
und Verbraucherschutz NRW, LANUV Az. 84-
02.04.2013. A072).
Flow cytometry analysis
BM and spleen cells from recipient mice were isolated as
described before [26]. Antibodies for immunophenotyping
applied in this study are available in Supplementary
Table S3.
Apoptosis assay
Apoptosis was analyzed using APC Annexin V Apoptosis
Detection Kit (BioLegend) according to the manufacturer’s
protocol.
Analysis of cell cycle phase
Cell cycle analysis was performed using propidium iodide.
Briefly, 2 × 106 cells were fixed with cold ethanol and
subsequently incubated with 100 µg/ml RNAse (Qiagen,
Hilden, Germany) and 50 µg/ml propidium iodide (Sigma-
Aldrich) for 30 min. Analysis was performed using FACS.
Proliferation assay
Cell proliferation was assessed via Trypan blue exclusion
method. Cell count was analyzed every 24 h for 4 days. To
analyze proliferation of CML, CD34+ CellTraceTM CFSE
Kit (Thermo Fisher Scientific) was used according to the
manufacturer’s protocol.
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Preparation and storage of reagents
Imatinib (IM) (LC Laboratories, Woburn, MA, USA)
was dissolved in dimethylsulfoxide (DMSO) and stored at
−20 °C in stocks of 10 mM. Ibr (Selleckchem, Houston,
TX, USA) was dissolved in DMSO at a stock concentration
of 10 mM and stored at −80 °C.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software (La Jolla, CA, USA). FACS data were analyzed
using FlowJo (Version 10) or Kalzua (Version 1.3) soft-
ware. Student’s two-sided t test or Mann–Whitney U test
were applied to compare the variability between two
groups. Multiple group analyses were performed using
one-way analysis of variance with Bonferroni’s multiple
comparison test. P < 0.05 was considered as statistically
significant. Error bars are given as standard derivation (s.
d.).We performed neither blinding nor randomization
within the animal experiments conducted in this study.
Results
Malignant FcγRIIb upregulation is not targeted by
TKI therapy
We previously identified upregulation of FcγRIIb
(CD32b) in LSK (lin−;c-kit+,Sca-1+) cells from trans-
genic SCLtTA/Bcr-Abl CML-CP mice (2.8-fold, p < 0.05)
by microarray analysis [26], and here we first confirmed
upregulation of the receptor by real-time quantitative PCR
(qRT-PCR) (FcγRIIb) and FACS analysis (CD32b) in
these malignant LSK cells (Fig. 1a). Next, we studied
murine C567BL/6 lin− BM cells that were virally trans-
duced to express Bcr-Abl. FcγRIIb messenger RNA
(mRNA) and protein levels were again found to be sig-
nificantly elevated in Bcr-Abl+ cells vs. ev controls
(Fig. 1b). Finally, we tested FcγRIIb mRNA expression in
CML vs. normal CD34+ cells and observed a 10.7-fold
increase in the human progenitor cell population (Fig. 1c).
We proceeded to examine if TKI treatment could revert
malignant FcγRIIb upregulation. CML cells from trans-
genic mice (Fig. 1d) and human CML cell lines K562 and
KCL-22 (Fig. 1e) were treated with IM and this showed
persisting FcγRIIb expression; TKI treatment even
enhanced FcγRIIb mRNA expression in the latter cell line.
As it has been shown that FcγRIIb expression is increased
by the anti-inflammatory cytokine IL-4 [27], we analyzed
publicly available microarray data for IL-4 expression in
CML patients (GSE13159 and GSE13164, probe set id:
207539_s_at). IL-4 expression was significantly increased
in CML vs. normal samples (Fig. 1f). In agreement,
addition of IL-4 was able to increase FcγRIIb mRNA
expression levels in the CML cell line KCL-22, and
combined treatment with TKI could not antagonize ele-
vated IL-4 expression, but even enhanced this effect
(Supplementary Fig. S1), suggesting that TKI-persisting
malignant upregulation could be mediated via altered
cytokine levels in CML.
FcγRIIb depletion impairs leukemic stem and
progenitor cell function
In order to study the effect of receptor targeting in
malignant cells, we next applied lin− BM cells from
FcγRIIb+/+ and FcγRIIb−/− mice that were virally infec-
ted to express Bcr-Abl or ev control. Colony-forming unit
(CFU) assays using Bcr-Abl+ or ev lin− FcγRIIb+/+ and
FcγRIIb−/− cells revealed significantly decreased colony
numbers upon receptor depletion specifically in Bcr-Abl+
cells (Fig. 2a). Moreover, CFU numbers were strongly
reduced upon re-plating, suggesting reduced stem cell
function of leukemic FcγRIIb−/− cells (Fig. 2a). As lin−
cells represent a rare cell population, we immortalized
stem and progenitor cells using an estradiol regulated
Hoxb8 approach [22]. We confirmed reduced clonogenic
potential upon FcγRIIb knockout likewise in these cells
(Supplementary Fig. S2). Next, we analyzed cell pro-
liferation from immortalized leukemic FcγRIIb+/+ vs.
FcγRIIb−/− cells. FcγRIIb knockout significantly
impaired proliferation in Bcr-Abl positive (Fig. 2b), but
not Bcr-Abl-negative control cells (Supplementary
Fig. S3). We proceeded to perform cell cycle analysis.
Deficiency of FcγRIIb increased the G0/G1 cell fraction,
while S and G2/M phases were decreased (Fig. 2c). No
cell cycle alterations were observed in ev control cells
(Supplementary Fig. S4). Analyses of negative cell cycle
regulator p27Cip1 revealed increased protein expression in
leukemic FcγRIIb knockout cells (Supplementary
Fig. S5). Moreover, we observed increased RNA expres-
sion of the negative cell cycle regulators p16Ink4A, p19Arf,
and p27Cip1, but not p21Cip/Waf1, upon FcγRIIb depletion
in Bcr-Abl-positive cells (Supplementary Fig. S6). Taken
together, these data show impaired malignant, but not
normal stem and progenitor cell function upon FcγRIIb
targeting.
FcγRIIb knockout or knockdown impairs CML
development in vivo
In order to study FcγRIIb function in vivo, we applied
both a Bcr-Abl transduction model combined with genetic
receptor depletion (Fig. 3a, model A) as well as strongly
reduced FcγRIIb expression mediated by shRNA using
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the transgenic SCLtTA/Bcr-Abl CML mouse model
(Fig. 3a, model B). For the retroviral model, we trans-
planted FcγRIIb+/+ or FcγRIIb−/− Bcr-Abl-transduced
BM cells into syngeneic C57BL/6 recipients. C57BL/6
mice receiving FcγRIIb−/− Bcr-Abl-infected BM cells
revealed a significantly reduced white blood cell com-
pared to FcγRIIb+/+ Bcr-Abl-transplanted recipients
(Supplementary Fig. S7). Spleen weight of recipients was
analyzed upon autopsy 15 days after transplantation
revealing a significant reduction upon FcγRIIb depletion
(Fig. 3b). Vector-encoded GFP expression allowed for
FACS analysis of Bcr-Abl-positive leukemic cells and
revealed a reduction in total BM (4.19-fold) and spleen
(2.62-fold) upon transplantation of FcγRIIb−/− Bcr-Abl
compared to FcγRIIb+/+ Bcr-Abl BM (Fig. 3c). More-
over, FcγRIIb depletion reduced leukemic LSK cells by
2.19-fold (Fig. 3c). Next, we applied shRNA-mediated
knockdown of FcγRIIb in vitro and in vivo using the
SCLtTA/Bcr-Abl transgenic CML mouse model (Fig. 3a,
model B).
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Fig. 1 FcγRIIb is upregulated in murine and human leukemic
stem cells. a FcγRIIb RNA and protein expression were analyzed in
LSK+ cells (lin−;Sca-1+;c-kit+) from transgenic SCLtTA/Bcr-Abl
mice that had been induced to express Bcr-Abl vs. controls. FACS
sorted LSK+ from 3 weeks induced mice were analyzed using qRT-
PCR (n= 3/3). The cell surface expression of FcγRIIb (CD32b) was
assessed by FACS in mice that had been induced for 6 days (n= 3/3).
b Lineage-depleted BM cells from C567B/L6 wild-type mice were
virally transduced to express Bcr-Abl or empty vector (ev) control.
Transduced cells were FACS sorted and analyzed for FcγRIIb
expression using qRT-PCR (left) and western blot analysis (right).
c FcγRIIb mRNA expression was analyzed in CD34+ healthy control
(HC) and CML patient samples (n= 5/9). d Lineage negative (lin−)
BM cells from transgenic SCLtTA/Bcr-Abl mice vs. controls were
analyzed for FcγRIIb expression before and after 2 µM imatinib (IM)
treatment for 18 h. e K562 and KCL-22 cells were treated for 18 h with
5 µM imatinib. f Public available microarray data from the leukemia
MILE study (#GSE13159 and #GSE13164, probe set id: 207539_s_at)
from BM biopsy of healthy control (HC) and CML patients at first
diagnosis (CML) were analyzed for IL-4 expression (n= 73/76). Data
are shown as mean ± SD. *p < 0.05, **p < 0.001, ***p < 0.0001, and
n.s. not statistically significant.
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Therefore, we first determined FcγRIIb knockdown
efficiency on mRNA and protein level using different
shRNAs (Supplementary Fig. S8). We identified shRNA#3
that showed the strongest knockdown on protein expression
and proceeded to reduce FcγRIIb expression using this
shRNA; hereafter, named shRNA:FcγRIIb. We first asses-
sed proliferation of immortalized SCLtTA/Bcr-Abl BM
cells and this was significantly impaired due to FcγRIIb
knockdown (Supplementary Fig. S9). Likewise, clonogenic
potential was drastically reduced upon FcγRIIb knockdown
(9.95-fold, Supplementary Fig. S10). We then transplanted
shRNA:FcγRIIb- or scr:shRNA-transduced control BM
cells from SCLtTA/Bcr-Abl (CD45.1) into FVB/N
(CD45.2) mice. Recipients were sacrificed 18 days after
transplantation for analyses. Spleen weight was assessed
upon autopsy and revealed a significant reduction in
SCLtTA/Bcr-Abl shRNA:FcγRIIb-transplanted recipients
compared to SCLtTA/Bcr-Abl shRNA:scr control mice
(Fig. 3d). shRNA-infected cells were identified via the
vector-encoded GFP expression and were reduced in BM
(1.42-fold) and spleen (1.73-fold) upon FcγRIIb knock-
down (Fig. 3e). Next, we analyzed LSK cells in this model
revealing a 1.38-fold decrease upon FcγRIIb targeting
(Fig. 3e). These effects were less severe as compared to
complete depletion of the receptor (Fig. 3c), likely reflecting
residual FcγRIIb expression/activity in the knockdown vs.
knockout model.
Malignant FcγRIIb signaling mediates BTK
activation in leukemic progenitors
We next studied the role of FcγRIIb-induced signal trans-
duction employing, the immortalized FcγRIIb−/− and
FcγRIIb+/+ progenitor cell model. As expected,
pSTAT5Y694 and pCRKLY207 were present in leukemic
FcγRIIb−/− and FcγRIIb+/+ Bcr-Abl positive cells (Fig. 4a).
Interestingly, we identified reduced phosphorylation levels
of Bruton’s tyrosine kinase (BTKY223), ERK1/2Y202/204 and
p38Y180/182 in leukemic cells that were depleted for FcγRIIb.
BTK total protein was likewise decreased. To analyze if
reduced BTK signaling is truly FcγRIIb-dependent in Bcr-
Abl-positive cells, we transduced FcγRIIb−/− BM using an
FcγRIIb-encoding virus. Western blot analyses confirmed
that pBTK was largely restored upon re-introduction of the
receptor in FcγRIIb−/− cells (Fig. 4b). As we observed
reduced CFU potential upon FcγRIIb depletion in malignant
cells (Fig. 2a), we proceeded to test the effect of FcγRIIb
restoration also on the clonogenic potential. Upon re-
integration of FcγRIIb into leukemic knockout cells, CFU
numbers significantly increased again (Fig. 4c). Leukemic
FcγRIIb−/− cells tended to form smaller and more diffuse
colonies, compared to leukemic FcγRIIb+/+ cells. This
effect was dependent on FcγRIIb, as cells with restored
receptor expression again formed colonies similar to leu-



























Fig. 2 FcγRIIb knockout reduces leukemic clonogenic potential
and cell proliferation. a Bcr-Abl and ev (empty vector) infected lin−
BM cells from FcγRIIb+/+ and FcγRIIb−/− (1000 cells/ml) were see-
ded in methylcellulose with or without cytokines. Numbers of colonies
(colony-forming units, CFUs) were assessed after 7 days. Re-plating
was performed using 1 × 104 cells. CFU numbers were counted after
7 days. b Proliferation assay using FcγRIIb+/+ and FcγRIIb−/− Bcr-
Abl+ cells was performed using Trypan blue exclusion method. c Cell
cycle was assessed in FcγRIIb+/+ and FcγRIIb−/− Bcr-Abl+ cells. Data
are shown as mean ± SD. n= 3, each, *p < 0.05, **p < 0.001, ***p <
0.0001, and n.s. not statistically significant.
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Fig. 3 Loss or reduction of FcγRIIb attenuates CML development
and reduces leukemic LSK cells in vivo. a Schematic illustration of
bone marrow transplantation approach using either FcγRIIb+/+ and
FcγRIIb−/− C567B/L6 cells that were virally transduced to express
Bcr-Abl (model A) or SCLtTA/Bcr-Abl FVB/N-derived BM cells
that were transduced to express shRNA targeting FcγRIIb (model B).
b Spleen weight of transplanted recipients receiving FcγRIIb+/+:
Bcr-Abl (n= 3) or FcγRIIb−/−:Bcr-Abl (n= 5) BM cells. c Total
leukemic GFP+ cells in BM, spleen, and BM LSK compartment.
d Spleen weight of FVB/N recipient mice transplanted with SCLtTA/
Bcr-Abl BM cells that were transduced with either shRNA:scr control
or shRNA:FcγRIIb. e Total leukemic GFP+ cells in BM, spleen, and





















Fig. 4 FcγRIIb mediates malignant BTK activation in Bcr-Abl-
positive cells. a Western blot analyses of immortalized FcγRIIb+/+
and FcγRIIb−/− Bcr-Abl and ev (empty vector) BM cells were per-
formed using the indicated antibodies. b FcγRIIb was retrovirally
introduced into FcγRIIb−/−:Bcr-Abl cells and protein lysates were
analyzed for BTK and ERK1/2 activation. c CFU assay using FcγRIIb
+/+:ev, FcγRIIb−/−:ev, FcγRIIb+/+:Bcr-Abl, FcγRIIb−/−:Bcr-Abl, or
FcγRIIb−/−:Bcr-Abl:FcγRIIb cells. Colony numbers were counted
7 days after seeding. Data are shown as mean ± SD. **p < 0.001 and
***p < 0.0001.
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Inhibition of Bcr-Abl combined with Ibr therapy
reduces malignant potential and enhances
apoptosis in nondividing CML-CP LSCs
As we identified BTK as a downstream target of FcγRIIb
signaling in murine CML cells, we proceeded to study BTK
phosphorylation in Bcr-Abl-positive K562 cells upon TKI
treatment. As expected, Ibr treatment significantly
decreased pBTK, but did not affect Bcr-Abl-induced sig-
naling (Fig. 5a). In contrast, IM treatment abolished pBcr-
Abl and pSTAT5 levels, but only mildly reduced pBTK
providing a rationale for dual targeting. As it has been
reported that Ibr treatment reduces Bcr-Abl kinase activity
in a murine progenitor cell line [28], we first treated 32D
Bcr-Abl-expressing cells. In line with these results, we
observed reduced Bcr-Abl phosphorylation upon increasing
Ibr concentration in the murine cell line model (Supple-
mentary Fig. S12). However, in human CML Ibr treatment
had only mild effects on pBcr-Abl and this was not
enhanced even by increasing concentrations up to 2.5 µM
(Fig. 5a). Next, we evaluated the effect of combined BTK
and Bcr-Abl inhibition on MNCs and CML CD34+ cells.
MNCs showed reduced CFU capacity upon IM and inter-
estingly also upon Ibr treatment alone and administered
together both drugs further reduced CFU numbers (Fig. 5b).
Likewise, in CML CD34+ cells Ibr treatment significantly
decreased colony formation compared to DMSO (Fig. 5c).
Combined Ibr and IM therapy further reduced colony
numbers compared to single TKI treatment in all samples
tested (Fig. 5c). Protein expression analysis of CML CD34+
cells revealed that Ibr inhibited BTK phosphorylation, while
STAT5 activation was not affected, confirming that Bcr-Abl
downstream signaling remained unaffected by Ibr. Also, IM
treatment alone did not affect pBTK levels (Fig. 5d).
Combined BTK and Bcr-Abl inhibition reduced prolifera-
tion of TKI-insensitive quiescent (CFSEMax) CD34+ CML
stem cells, yielding more cells with no or one division as
compared to single IM treatment (Fig. 5e, Supplementary
Figs. S13+ S14). However, apoptosis FACS of nondivid-
ing CFSEMax CD34+ cells revealed a significant increase in
the quiescent CML cell population (Fig. 5f, Supplementary
Figs. S15+ S16), showing that combined treatment not
only reduces the stem cell quality of CML cells, but also
induces apoptosis in this therapy-resistant cell population.
In conclusion, Ibr as an FDA-approved drug could therefore
provide a novel therapeutic approach to overcome resis-
tance in CML stem cells.
Discussion
A variety of clinical trials has revealed that TKI dis-
continuation in optimal responding patients allows for TFR
in about half of this selected patient cohort. Thereby, a
minimum of 2 years of continued therapy in deep molecular
response seems to be beneficial [5, 29], but beyond that the
effect on TFR is largely unchanged either by further therapy
duration or the type of TKI tested [6, 30, 31], showing that
Bcr-Abl-independent mechanisms must be targeted to
increase TFR rates in patients, ideally using already
approved drugs.
Here we show a critical function of the inhibitory ITIM-
receptor FcγRIIb in CML stem cell persistence and ther-
apeutic targeting of malignant FcγRIIb-mediated signaling
enhanced TKI-mediated cell death in CML stem cells.
A positive role of ITIM-receptor signaling for HSC
function in AML has previously been shown. The ITIM-
receptor LIRB2 and its mouse homologous PirB are
expressed on human and mouse HSCs, where their binding
to angiopoietin-like proteins supports stem cell expansion.
Genetic depletion of PirB enhanced differentiation and
impaired MLL-AF9 AML development in vivo and LSC
survival [20, 32]. In ALL activation of the ITIM-receptor
platelet endothelial cell adhesion molecule 1 (PECAM-1),
CD300A, and LAIR1 has been shown to compensate for
excessive signaling in B cells that is mediated through
recruitment of the inhibitory phosphatases PTPN6 and
INPP5D [33]. In CML the role of ITIM-receptor signaling
has hardly been studied so far. Using human cell lines, the
ITIM-receptor PECAM-1 was found to antagonize IM-
induced apoptosis [34], but genetic depletion of PECAM-1
in a retroviral model of CML-like disease showed no effect
on CML myeloid progenitor viability or clonogenic
potential in vitro [33].
Here we at first identified TKI-resistant FcγRIIb upre-
gulation in murine and human CML stem and progenitor
cells. Cytokines such as IL-4 or IL-10 are known to induce
FcγRIIb upregulation [27, 35] and, indeed, we could con-
firm IL-4-mediated FcγRIIb upregulation in malignant cells
that was not decreased upon TKI treatment. Concordantly,
expression of the IL-4 receptor alpha chain was significantly
upregulated (2.23-fold, p= 0.0062, data not shown) in
CML vs. normal LSK cells in our microarray analysis of the
transgenic SCLtTA/Bcr-Abl mouse model [26], which
likewise showed FcγRIIb upregulation. IL-4 was previously
found to be increased in the plasma of CML patients [36]
and corresponding to this IL-4 secretion by the malignant
clone has been shown for K562 and BA/F3:Bcr-Abl CML
cells, where IL-4 secretion antagonized IM-induced apop-
tosis [37]. Moreover, downregulation of IL-4 is evident in
unfractionated BM or pB leukocytes from cytogenetic
responders vs. non-responders [38] (Supplementary
Fig. S17), and taken together, these data suggest that IL-4
could be a candidate for permitting TKI-persisting FcγRIIb
upregulation. Further analyses correlating IL-4 serum levels
with pBTK ideally in LSCs from patients who remain in or
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not remain in TFR after TKI discontinuation would (1)
further underline the significance of pBTK in LSC resis-
tance and (2) could unravel the potential of IL-4 or pBTK
being a biomarker that would allow predicting the outcome
of TKI discontinuation.
By using FcγRIIb−/− BM cells, we identified markedly
decreased clonogenic potential, particularly apparent upon
serial re-plating, suggesting that primitive hematopoietic
cells are notably affected by FcγRIIb targeting. Colonies
that were generated by Bcr-Abl-positive FcγRIIb−/− cells
were less compact and more diffuse compared to Bcr-Abl-
positive FcγRIIb+/+ cells, and more diffuse colonies indi-
cate an increased differentiation potential [39]. Decreased
CFU potential and colony morphology could be largely
rescued by reconstituting FcγRIIb expression. Transplan-
tation of FcγRIIb−/− BM cells into recipient mice impaired
the CML phenotype, including a reduction of leukemic
LSK cells using a retroviral and transgenic CML mouse
model. Reduced malignant cell expansion is in line with
decreased proliferation in malignant FcγRIIb-depleted or
SCLtTA/Bcr-Abl FcγRIIb shRNA-transduced cells. More-
over, we observed a strong increase in negative cell cycle
regulators p16Ink4A, p19Arf, and p27Cip1 in leukemic FcγRIIb
−/− cells. These effects were only evident in malignant, but
not in Bcr-Abl-negative FcγRIIb−/− cells. Activation of cell
cycle checkpoint molecules due to ITIM-receptor knockout
was previously reported in Bcr-Abl-positive pre-B cells
[33]. In this model, ITIM-receptor depletion resulted simi-
larly in cell cycle arrest and complete loss of CFU potential.
The FcγRIIb ITIM motif can be phosphorylated
by SRC family kinase LYN [18]. It has been shown that
LYN-mediated FcγRIIb phosphorylation results preferentially
in recruitment of SHIP1 (INPP5D) in vivo [40–42]. SHIP1
then hydrolyses 5′-phosphate of phosphatidylinositol-3,4,5-
trisphosphate, which alters the interaction of various signaling
molecules with the plasma membrane, thereby affecting
intracellular signal transduction. In contrast to published data
where SHIP1-dependent FcγRIIb signaling attenuates ERK1/2
activation [43], we observed reduced ERK1/2 phosphorylation
due to FcγRIIb deficiency in leukemic cells. Similarly, we
observed diminished BTK activation due to FcγRIIb knockout
in malignant cells that could be restored upon rescued FcγRIIb
expression. Global phosphotyrosine profiling previously
identified an activated BTK-derived peptide in Bcr-Abl-
expressing BA/F3 cells [44]. Applying the BTK inhibitor
LFM-A13 on Bcr-Abl+ cell lines reduced cell viability similar
to IM [45]. A further report studying BTK function by
pharmacologic inhibition using PC-005 to inhibit BTK like-
wise showed reduced growth of a Bcr-Abl+ murine BA/F3
lymphoid progenitor cell line, but this was associated with off-
drug target effects reducing Bcr-Abl kinase activity [28]. We
have observed similar reduction of pBcr-Abl upon BTK
inhibition using Ibr in murine Bcr-Abl-expressing 32D cell
line. However, in human K562 CML cells as well as patient-
derived CML CD34+ cells, no drastically altered Bcr-Abl or
STAT5 phosphorylation was evident upon Ibr treatment.
Our data show elevated BTK protein expression in Bcr-
Abl-positive transgenic cells, in the presence of FcγRIIb.
Upon depletion of the receptor, BTK protein significantly
decreases in malignant cells and this is partially restored by
reconstituting FcγRIIb expression. Expression of total ERK
or p38 protein is not affected by FcγRIIb depletion. Despite,
phosphorylation of these targets is Bcr-Abl dependent, as
expected. To this end, it has been shown that inhibition of
Bcr-Abl kinase activity by IM significantly decreases
phosphorylation of ERK1/2 or p38, while total protein
remained unaffected [46]. Moreover, in a model of
doxycycline-regulated Bcr-Abl expression, reversion of
Bcr-Abl altered the level of ERK1/2 or p38 phosphoryla-
tion, while the total protein did not change [47]. However,
the underlying mechanism that results in BTK protein
reduction upon FcγRIIb depletion in malignant cells is
unclear. It has been shown that BTK can induce its own
transcription by a nuclear factor-κB (NF-κB)-dependent
mechanism [48]. In addition, the FcγRIIb itself is induced
upon NF-κB stimulation [49]. Along these lines, NF-κB is
activated in CML cells despite Bcr-Abl inhibition, down-
stream of, for example, IL-1 [15] or TNF signaling [50].
Moreover, activation of NF-κB downstream of IL-4 has
been shown [51] and our data already suggest that IL-4 is
involved in TKI-resistant FcγRIIb upregulation (Fig. 1f and
Supplementary Fig. S1). Interestingly, the deletion of the γ-
chain subunit in FcγR knockout mice blocked NF-κB
activation in these mice [52]. Therefore, it is tempting to
Fig. 5 Combined inhibition of Bcr-Abl and BTK impairs clono-
genic potential, reduces proliferation, and enhances apoptosis in
nondividing LSCs. a K562 cells were treated with increasing con-
centrations of Ibr (Ibrutinib, 0.5–2.5 µM) or IM (Imatinib, 0.5–2.5 µM)
for 18 h. Subsequently, protein lysates were analyzed for pBcr-Abl,
pSTAT5, pBTK, Bcr-Abl, STAT5, BTK, and GAPDH. b Primary
CML MNCs (10,000 cells/ml) were treated for 48 h (c) and CML
CD34+ cells (1000 cells/ml) for 72 h with Ibr (0.5 µM, 2.5 µM), IM
(2.5 µM, 5.0 µM), or the combination of both drugs. Cells were
resuspended and plated using methylcellulose-containing cytokines.
CFU numbers were counted after 7 days (n= 3, each). d CML CD34+
cells were treated for 72 h with 2.5 µM Ibr, 5.0 µM IM, and the
combination of both drugs. Protein lysates were analyzed for pSTAT5,
pBTK, pERK1/2, STAT5, BTK, and ERK1/2. e Evaluation of cell
divisions in CML CD34+ cells upon treatment using CFSE combined
with FACS analyses. For a clear presentation, the level of significance
is given for Ibr+ IM vs. IM only. f Annexin V+ staining of undivided
CFSEMax cells in treated CML CD34+ cells. g Proposed mechanism:
elevated FcγRIIb expression in malignant cells persists despite BCR-
ABL inhibition and this could be mediated via inflammatory cytokines
in the CML microenvironment. FcγRIIb activity results in
increased BTK expression and phosphorylation and dual targeting of
BCR-ABL and BTK activity induces apoptosis in LSCs. Data are
shown as mean ± SD. *p < 0.05, **p < 0.001, ***p < 0.0001, and n.s.
not statistically significant.
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speculate that BTK protein could be upregulated via NF-κB
in malignant FcγRIIb-expressing cells and it would be
highly interesting to study the effect of FcγRIIb depletion
on NF-κB-mediated BTK activation in our model.
Simultaneous administration of Ibr and IM was superior
in reducing the clonogenic potential of CML-CP patient-
derived MNCs and primitive CD34+ cells compared to
single TKI application. Moreover, Bcr-Abl inhibition
combined with Ibr treatment increased apoptosis in quies-
cent CML-CP LSCs.
The BTK inhibitor Ibr is already approved for the
treatment of CLL and mantle cell lymphoma and was fur-
ther effective in pre-clinical AML studies, multiple mye-
loma, and pre-BCR B-ALL [53–55]. It has to be considered
that Ibr therapy is associated with considerable toxicity,
including atrial fibrillation, bleeding, neutropenia, and
infections, as well as gastrointestinal symptoms [56–58].
Careful selection of patients and dosing will be important
for phase I and II combination trials. In addition, given the
current cost of Ibr, the potential treatment regime should be
carefully elaborated. We could envision short-term Ibr
treatment in patients who are already eligible for TKI dis-
continuation due to deep molecular remission. In these
patients, Ibr could either replace Bcr-Abl-directed TKI
therapy or be administered together with Bcr-Abl inhibition
for a defined period. Molecular monitoring in close intervals
during and after therapy could then unravel if TFR rate
could be increased using this strategy. If toxicity is accep-
table, the cost at long term would be reduced if a higher rate
of patients will obtain TFR.
This study shows that BTK inhibition by the FDA-
approved drug Ibr significantly affects LSC survival in
CML and hence targeting the Bcr-Abl–FcγRIIb–BTK axis
is a novel therapeutic strategy contributing to the eradica-
tion of therapy-resistant LSCs.
Acknowledgements We thank Kristina Feldberg and Julia Plum for
excellent technical assistance. This work was financially supported by
the DFG (Deutsche Forschungsgemeinschaft, GZ: SCHE 1938/1-1,
grant holder: MS) and by the Medical faculty of the RWTH Aachen
(START 691706, grant holder: MS). We also thank Hans Häcker for
providing the MSCV-ERBDH-HoxB8-Neo plasmid. Open access
funding provided by Projekt DEAL.
Author contributions OP performed experiments, analyzed the data,
designed research, and wrote the manuscript. SL, MKK, and CW per-
formed experiments and wrote the manuscript. T.M., I.G.C., analyzed the
data. MH, SL, TB, NC, MC, THB, and SK contributed research material,
analyzed the data, and wrote the manuscript. MS designed research,
performed experiments, analyzed the data, and wrote the manuscript. All
authors approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest SK reports having served on Advisory Boards for
Pfizer, Incyte/Ariad, Novartis, AOP, BMS, and CTI; Honoraria:
Novartis, BMS, Pfizer, Incyte/Ariad, Shire, Janssen; Scientific
Research Support: Novartis Foundation, BMS, Novartis; Others:
Alexion. All the other authors declare that they have no conflict
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ,
Wen SC, Zon G, et al. Phosphatidylinositol-3 kinase activity is
regulated by BCR/ABL and is required for the growth of Phila-
delphia chromosome-positive cells. Blood. 1995;86:726–36.
2. Morgan MA, Dolp O, Reuter CW. Cell-cycle-dependent activa-
tion of mitogen-activated protein kinase kinase (MEK-1/2) in
myeloid leukemia cell lines and induction of growth inhibition
and apoptosis by inhibitors of RAS signaling. Blood.
2001;97:1823–34.
3. Zhang B, Li M, McDonald T, Holyoake TL, Moon RT,
Campana D, et al. Microenvironmental protection of CML stem
and progenitor cells from tyrosine kinase inhibitors through N-
cadherin and Wnt-beta-catenin signaling. Blood. 2013;121:
1824–38.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM,
et al. Efficacy and safety of a specific inhibitor of the BCR-ABL
tyrosine kinase in chronic myeloid leukemia. N Engl J Med.
2001;344:1031–7.
5. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F,
et al. Discontinuation of imatinib in patients with chronic myeloid
leukaemia who have maintained complete molecular remission for
at least 2 years: the prospective, multicentre Stop Imatinib (STIM)
trial. Lancet Oncol. 2010;11:1029–35.
6. Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-
Bresler A, et al. Discontinuation of dasatinib or nilotinib in
chronic myeloid leukemia: interim analysis of the STOP 2G-TKI
study. Blood. 2017;129:846–54.
7. Ross DM, Masszi T, Gomez Casares MT, Hellmann A, Stentoft J,
Conneally E, et al. Durable treatment-free remission in patients
with chronic myeloid leukemia in chronic phase following
frontline nilotinib: 96-week update of the ENESTfreedom study. J
Cancer Res Clin Oncol. 2018;144:945–54.
8. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW,
Druker BJ. Human chronic myeloid leukemia stem cells are
insensitive to imatinib despite inhibition of BCR-ABL activity. J
Clin Invest. 2011;121:396–409.
9. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S,
Allan EK, et al. Chronic myeloid leukemia stem cells are not
dependent on Bcr-Abl kinase activity for their survival. Blood.
2012;119:1501–10.
Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia 2645
10. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jorda-
nides N, et al. Dasatinib (BMS-354825) targets an earlier pro-
genitor population than imatinib in primary CML but does not
eliminate the quiescent fraction. Blood. 2006;107:4532–9.
11. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC,
Holyoake TL. Nilotinib exerts equipotent antiproliferative effects
to imatinib and does not induce apoptosis in CD34+ CML cells.
Blood. 2007;109:4016–9.
12. Kuepper MK, Butow M, Herrmann O, Ziemons J, Chatain N,
Maurer A, et al. Stem cell persistence in CML is mediated by
extrinsically activated JAK1-STAT3 signaling. Leukemia.
2019;33:1964–77.
13. Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J,
Massonnet G, et al. Erosion of the chronic myeloid leukaemia
stem cell pool by PPARgamma agonists. Nature. 2015;525:380–3.
14. Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K,
Williamson AJ, et al. Dual targeting of p53 and c-MYC selec-
tively eliminates leukaemic stem cells. Nature. 2016;534:341–6.
15. Zhang B, Chu S, Agarwal P, Campbell VL, Hopcroft L, Jorgensen
HG, et al. Inhibition of interleukin-1 signaling enhances elim-
ination of tyrosine kinase inhibitor-treated CML stem cells. Blood.
2016;128:2671–82.
16. Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake
TL, et al. Targeting mitochondrial oxidative phosphorylation
eradicates therapy-resistant chronic myeloid leukemia stem cells.
Nat Med. 2017;23:1234–40.
17. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science.
2000;290:84–89.
18. Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC,
Fridman WH, et al. Fc epsilon receptor I-associated lyn-dependent
phosphorylation of Fc gamma receptor IIB during negative reg-
ulation of mast cell activation. J Immunol. 1998;160:1647–58.
19. Iwasaki M, Kuwata T, Yamazaki Y, Jenkins NA, Copeland NG,
Osato M, et al. Identification of cooperative genes for NUP98-
HOXA9 in myeloid leukemogenesis using a mouse model. Blood.
2005;105:784–93.
20. Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang C, et al.
Inhibitory receptors bind ANGPTLs and support blood stem cells
and leukaemia development. Nature. 2012;485:656–60.
21. Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, et al. The ITIM-
containing receptor LAIR1 is essential for acute myeloid leukae-
mia development. Nat Cell Biol. 2015;17:665–77.
22. Wang GG, Calvo KR, Pasillas MP, Sykes DB, Hacker H, Kamps
MP. Quantitative production of macrophages or neutrophils
ex vivo using conditional Hoxb8. Nat Methods. 2006;3:287–93.
23. Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C,
Costa IG, et al. Mtss1 is a critical epigenetically regulated tumor
suppressor in CML. Leukemia. 2016;30:823–32.
24. Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M,
Stehling M, et al. Novel imatinib-sensitive PDGFRA-activating
point mutations in hypereosinophilic syndrome induce growth
factor independence and leukemia-like disease. Blood. 2011;117:
2935–43.
25. Schemionek M, Spieker T, Kerstiens L, Elling C, Essers M,
Trumpp A, et al. Leukemic spleen cells are more potent than bone
marrow-derived cells in a transgenic mouse model of CML.
Leukemia. 2012;26:1030–7.
26. Schemionek M, Elling C, Steidl U, Baumer N, Hamilton A,
Spieker T, et al. BCR-ABL enhances differentiation of long-term
repopulating hematopoietic stem cells. Blood. 2010;115:3185–95.
27. Pricop L, Redecha P, Teillaud JL, Frey J, Fridman WH, Sautes-
Fridman C, et al. Differential modulation of stimulatory and
inhibitory Fc gamma receptors on human monocytes by Th1 and
Th2 cytokines. J Immunol. 2001;166:531–7.
28. MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger
MW. Bruton’s tyrosine kinase is not essential for Bcr-Abl-
mediated transformation of lymphoid or myeloid cells. Leukemia.
2008;22:1354–60.
29. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi
T, et al. Discontinuation of imatinib in Japanese patients with
chronic myeloid leukemia. Haematologica. 2012;97:903–6.
30. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini
FE, Varet B, et al. Loss of major molecular response as a trigger
for restarting tyrosine kinase inhibitor therapy in patients with
chronic-phase chronic myelogenous leukemia who have stopped
imatinib after durable undetectable disease. J Clin Oncol.
2014;32:424–30.
31. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H,
Almeida A, et al. Discontinuation of tyrosine kinase inhibitor
therapy in chronic myeloid leukaemia (EURO-SKI): a pre-
specified interim analysis of a prospective, multicentre, non-ran-
domised, trial. Lancet Oncol. 2018;19:747–57.
32. Kang X, Cui C, Wang C, Wu G, Chen H, Lu Z, et al. CAMKs
support development of acute myeloid leukemia. J Hematol
Oncol. 2018;11:30.
33. Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, et al.
Signalling thresholds and negative B-cell selection in acute lym-
phoblastic leukaemia. Nature. 2015;521:357–61.
34. Wu N, Kurosu T, Oshikawa G, Nagao T, Miura O. PECAM-1 is
involved in BCR/ABL signaling and may downregulate imatinib-
induced apoptosis of Philadelphia chromosome-positive leukemia
cells. Int J Oncol. 2013;42:419–28.
35. Joshi T, Ganesan LP, Cao X, Tridandapani S. Molecular analysis
of expression and function of hFcgammaRIIbl and b2 isoforms in
myeloid cells. Mol Immunol. 2006;43:839–50.
36. Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M,
Busfield SJ, et al. TGF-alpha and IL-6 plasma levels selectively
identify CML patients who fail to achieve an early molecular
response or progress in the first year of therapy. Leukemia.
2016;30:1263–72.
37. Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide
CA, O’Hare T, et al. Wnt/Ca2+/NFAT signaling maintains sur-
vival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer
Cell. 2010;18:74–87.
38. Crossman LC, Mori M, Hsieh YC, Lange T, Paschka P, Har-
rington CA, et al. In chronic myeloid leukemia white cells from
cytogenetic responders and non-responders to imatinib have
very similar gene expression signatures. Haematologica. 2005;90:
459–64.
39. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization
and leukemic transformation of a myelomonocytic precursor
by retrovirally transduced HRX-ENL. EMBO J. 1997;
16:4226–37.
40. Ono M, Bolland S, Tempst P, Ravetch JV. Role of the inositol
phosphatase SHIP in negative regulation of the immune system by
the receptor Fc(gamma)RIIB. Nature. 1996;383:263–6.
41. Bruhns P, Vely F, Malbec O, Fridman WH, Vivier E, Daeron M.
Molecular basis of the recruitment of the SH2 domain-containing
inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB. J
Biol Chem. 2000;275:37357–64.
42. Lesourne R, Bruhns P, Fridman WH, Daeron M. Insufficient
phosphorylation prevents fc gamma RIIB from recruiting the SH2
domain-containing protein-tyrosine phosphatase SHP-1. J Biol
Chem. 2001;276:6327–36.
43. Nakamura K, Brauweiler A, Cambier JC. Effects of Src
homology domain 2 (SH2)-containing inositol phosphatase
(SHIP), SH2-containing phosphotyrosine phosphatase (SHP)-
1, and SHP-2 SH2 decoy proteins on Fc gamma RIIB1-
effector interactions and inhibitory functions. J Immunol.
2000;164:631–8.
44. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O’Hare T, Lee
KA, et al. Kinase domain mutants of Bcr-Abl exhibit altered
2646 O. Parting et al.
transformation potency, kinase activity, and substrate utilization,
irrespective of sensitivity to imatinib. Mol Cell Biol.
2006;26:6082–93.
45. Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M,
Wartenberg M, et al. Mimicry of a constitutively active pre-B cell
receptor in acute lymphoblastic leukemia cells. J Exp Med.
2005;201:1837–52.
46. Martin-Rodriguez P, Guerra B, Hueso-Falcon I, Aranda-Tavio H,
Diaz-Chico J, Quintana J, et al. A novel
naphthoquinone–coumarin hybrid that inhibits BCR-ABL1-
STAT5 oncogenic pathway and reduces survival in imatinib-
resistant chronic myelogenous leukemia cells. Front Pharm.
2018;9:1546.
47. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y,
et al. A common signaling cascade may underlie “addiction” to
the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell.
2006;10:425–35.
48. Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE,
Bjorkstrand B, et al. Proteasome-dependent autoregulation of
Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood.
2008;111:4617–26.
49. Jhou JP, Chen SJ, Huang HY, Lin WW, Huang DY, Tzeng SJ.
Upregulation of FcgammaRIIB by resveratrol via NF-kappaB
activation reduces B-cell numbers and ameliorates lupus. Exp Mol
Med. 2017;49:e381.
50. Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia
R, et al. Autocrine TNF-alpha production supports CML stem and
progenitor cell survival and enhances their proliferation. Blood.
2013;122:3335–9.
51. Thieu VT, Nguyen ET, McCarthy BP, Bruns HA, Kapur R,
Chang CH, et al. IL-4-stimulated NF-kappaB activity is required
for Stat6 DNA binding. J Leukoc Biol. 2007;82:370–9.
52. Cao S, Theodore S, Standaert DG. Fcgamma receptors are
required for NF-kappaB signaling, microglial activation and
dopaminergic neurodegeneration in an AAV-synuclein mouse
model of Parkinson’s disease. Mol Neurodegener. 2010;5:42.
53. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan
DJ. Identification of Bruton’s tyrosine kinase as a therapeutic
target in acute myeloid leukemia. Blood. 2014;123:1229–38.
54. Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, et al.
Bruton tyrosine kinase is a therapeutic target in stem-like cells
from multiple myeloma. Cancer Res. 2015;75:594–604.
55. Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang
BY, et al. Ibrutinib inhibits pre-BCR(+) B-cell acute lympho-
blastic leukemia progression by targeting BTK and BLK. Blood.
2017;129:1155–65.
56. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al.
Ibrutinib as initial therapy for patients with chronic lymphocytic
leukemia. N Engl J Med. 2015;373:2425–37.
57. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy
NM, et al. Ibrutinib versus ofatumumab in previously treated
chronic lymphoid leukemia. N. Engl J Med. 2014;371:213–23.
58. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS,
Grosicki S, et al. Ibrutinib combined with bendamustine and
rituximab compared with placebo, bendamustine, and rituximab
for previously treated chronic lymphocytic leukaemia or small
lymphocytic lymphoma (HELIOS): a randomised, double-blind,
phase 3 study. Lancet Oncol. 2016;17:200–11.
Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia 2647
